We are thrilled to post this very special interview with the creator of the world's most utilized, non-invasive liver disease assessment tool, FIB-4, Dr. Richard Sterling.
Is the test perfect? No. Will it identify patients who are at risk of having fibrosis, developing more serious liver disease and those who require further assessment? Yes.
Dr. Manal Abdelmalek, Hepatologist, Professor of Medicine at Duke University shares her expert opinion about what patients should ask their Primary Care Physician to ensure that their liver disease risks are assessed and that they are referred to a specialist for a more detailed evaluation if warranted.
Super excited to share this brand new data from our social media study on NAFLD and NASH! Will be presented at the upcoming CLM2021 conference and was presented at the 4th Annual NASH Summit Oral Poster Session.
What we found was pretty incredible!
Please click play for the audio and text - under 5 minutes total.
Screening for Fatty Liver Disease: Of the 363 million adults in North America, about 91 million may have fatty liver disease and not know it. How will we screen for that? Should we screen for that? Who is most at risk? All critical questions that need to be addressed.
Dr. Robert Gish discusses current screening options and benefits.
Dr. Supriya Joshi clearly explains how NAFLD and NASH are different. June 2020
Dr. Mark Swain explains what your Physician uses to diagnose NASH. There are specific markers that are considered.
A fibroscan can confirm if you have liver stiffness and scarring.
Nurse Practitioner, Cheryl Dale shows how easy a Fibroscan can be for patients and that there is nothing to be afraid of.
Biopsies are the current gold standard to diagnose NASH, but there may be other options that are less invasive to patients. Dr. Stefano Brillanti discusses this important topic.